Loop diuretic therapy in heart failure: The need for solid evidence on a fluid issue

Clinical Cardiology

Volumn 33, Issue 6, 2010, Pages 345-352

  Chiong, Jun R ^a,b   Cheung, Rebecca J ^b  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; ARGININE; BUMETANIDE; CREATININE; ELECTROLYTE; ETACRYNIC ACID; FUROSEMIDE; NEUROHORMONE; SODIUM POTASSIUM CHLORIDE COTRANSPORTER; THIAZIDE DIURETIC AGENT; TORASEMIDE; VASODILATOR AGENT; VASOPRESSIN; LOOP DIURETIC AGENT;

ACUTE DECOMPENSATED HEART FAILURE; ADRENERGIC SYSTEM; ALDOSTERONE URINE LEVEL; ARTIFICIAL VENTILATION; BODY WEIGHT; CLINICAL STUDY; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; CORONARY HEMODYNAMICS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESISTANCE; DRUG URINE LEVEL; DYSPNEA; ELECTROLYTE TRANSPORT; ENZYME ACTIVITY; GASTROINTESTINAL MOTILITY; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE OVERLOAD; HEART OUTPUT; HOSPITALIZATION; HUMAN; INFORMATION RETRIEVAL; KIDNEY FAILURE; LUNG EDEMA; MEDLINE; MITRAL VALVE REGURGITATION; MORTALITY; NORADRENALIN BLOOD LEVEL; PLASMA RENIN ACTIVITY; PRACTICE GUIDELINE; PROTEIN BINDING; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; STOMACH EMPTYING; TREATMENT INDICATION; TREATMENT RESPONSE; URINARY EXCRETION; URINE VOLUME; VASCULAR RESISTANCE; VENOUS CONGESTION; DRUG EFFECTS; ELECTROLYTE BALANCE; EVIDENCE BASED MEDICINE; INFUSION; INJECTION; KIDNEY; PATHOPHYSIOLOGY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

DRUG RESISTANCE; EVIDENCE-BASED MEDICINE; HEART FAILURE; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS; KIDNEY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTORS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; TREATMENT OUTCOME; WATER-ELECTROLYTE BALANCE;

EID: 77953836396     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20771     Document Type: Review

References (56)

1. Cuffe MS, Califf RM, Adams KF Jr, et al; for OPTIME-CHF Investigators. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541-1547.
2. Mebazaa A, Nieminen MS, Packer M, et al; for SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297:1883-1891. (Pubitemid 46707842)
3. Silke B. Central hemodynamic effects of diuretic therapy in chronic heart failure. Cardiovasc Drugs Ther. 1993;7(Suppl. 1):45-53. (Pubitemid 23113598)
4. Stevenson LW, Brunken RC, Belil D, et al. Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. J Am Coll Cardiol. 1990;15:174-180.
5. Drug Topics magazine. Table of top 200 generic drugs by total prescriptions, 2008. http://drugtopics.modernmedicine.com/top200gen. Accessed September 24, 2009.
6. Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387-395.
7. Rocco TP, Fang JC. Pharmacotherapy of congestive heart failure. In: Brunton LL, Lazo JS, Parker KL, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 11th ed. New York, NY: McGraw-Hill; 2006; 874.
8. Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6.
9. Nicholls MG. Interaction of diuretics and electrolytes in congestive heart failure. Am J Cardiol. 1990;65:E E 17-23.
10. Müller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV - efficacy and quality of life. Eur J Heart Fail. 2003;5:793-801. (Pubitemid 38198067)
11. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513-520.
12. Brater DC. Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J. 1994;72:S40-S43. (Pubitemid 24249726)
13. Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002;144:31-38. (Pubitemid 34734752)
14. Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106:90-96. (Pubitemid 29077144)
15. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005;3:CD003178.
16. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97:1759-1764. (Pubitemid 43817867)
17. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006;27:1431-1439. (Pubitemid 43998077)
18. Ahmed A, Young JB, Love TE, Levesque R, Pitt B. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol. 2008;125:246-253. (Pubitemid 351400220)
19. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064-1069. (Pubitemid 47451811)
20. Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol. 1997;80:519-522. (Pubitemid 27371765)
21. Peacock WF, Costanzo MR, De Marco T, et al; for ADHERE Scientific Advisory Committee and Investigators. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009;113:12-19.
22. Wright SP, Verouhis D, Gamble G, Swedberg K, Sharpe N, Doughty RN. Factors influencing the length of hospital stay of patients with heart failure. Eur J Heart Fail. 2003;5:201-209. (Pubitemid 36383630)
23. Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589-596.
24. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429-1435.
25. Fonarow GC, Adams KF Jr, Abraham WT, et al; for ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA. 2005;293:572-580.
26. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation. 1990;82:1724-1729. (Pubitemid 20367975)
27. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J. 1987;57:17-22. (Pubitemid 17216948)
28. Galve E, Mallol A, Catalan R, et al. Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized heart failure and systolic dysfunction. Eur J Heart Fail. 2005;7:892-898. (Pubitemid 41125913)
29. Jaronik J, Mikkelson P, Fales W, Overton DT. Evaluation of prehospital use of furosemide in patients with respiratory distress. Prehosp Emerg Care. 2006;10:194-197.
30. Van Kraaij DJ, Jansen RW, Gribnau FW, Hoefnagels WH. Use of diuretics and opportunities forwithdrawal in a Dutch nursing home population. Neth J Med. 1998;53:20-26.
31. Mosesso VN Jr, Dunford J, Blackwell T, Griswell JK. Prehospital therapy for acute congestive heart failure: state of the art. Prehosp Emerg Care. 2003;7:13-23. (Pubitemid 36091793)
32. Poole-Wilson PA. Treatment of acute heart failure: out with the old, in with the new. JAMA. 2002;287:1578-1580.
33. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464-474. (Pubitemid 36286188)
34. National Institutes of Health, Clinical Trials Web site. Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study). http://www.clinicaltrials.gov/ct2/show/ NCT00577135?term=DOSE-AHF&rank=1. Accessed September 24, 2009.
35. Cody RJ, Covit AB, Schaer GL, Laragh JH, Sealey JE, Feldschuh J. Sodium and water balance in chronic congestive heart failure. J Clin Invest. 1986;77:1441-1452.
36. Hunt SA, Abrahams WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1-e90.
37. European Society of Cardiology, Heart Failure Association of the ESC (HFA), European Society of Intensive Care Medicine (ESICM), et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 2008;10:933-989.
38. Arnold JM, Liu P, Demers C, et al. Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management. Can J Cardiol. 2006;22:23-45.
39. Heart Failure Society of America. Evaluation and management of patients with acute decompensated heart failure. J Card Fail. 2006;12:e86-e103.
40. Heart Failure Society of America. Heart failure in patients with left ventricular systolic dysfunction. J Card Fail. 2006;12:e38-e57.
41. Domanski M, Norman J, Pitt B, et al. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 2003;42:705-708.
42. Paterna S, Parrinello G, Cannizzaro S, et al. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. Am J Cardiol. 2009;103:93-102.
43. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43:61-67.
44. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 2004;147:331-338.
45. Walma EF, Hoes AW, van Dooren C, et al. Withdrawal of long-term diuretic medication in elderly patients: a double blind randomised trial. BMJ. 1997;315: 464-468.
46. De Jonge JW, Knottnerus JA, van Zutphen WM, et al. Short term effect of withdrawal of diuretic drugs prescribed for ankle oedema. BMJ. 1994;308:511-513.
47. Burr ML, King S, Davies HE, et al. The effects of discontinuing long-term diuretic therapy in the elderly. Age Ageing. 1977;6:38-45.
48. Myers MG, Weingert ME, Fisher RH, et al. Unnecessary diuretic therapy in the elderly. Age Ageing. 1982;11:213-221.
49. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76: 1259-1265.
50. Sherman LG, Liang CS, Baumgardner S, et al. Piretanide, a potent diuretic with potassium-sparing properties, for the treatment of congestive heart failure. Clin Pharmacol Ther. 1986;40:587-594.
51. Cheitlin MD, Byrd R, Benowitz N, et al. Amiloride improves hemodynamics in patients with chronic congestive heart failure treated with chronic digoxin and diuretics. Cardiovasc Drugs Ther. 1991;5:719-725.
52. Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison of captopril alone against frusemide plus amiloride in mild heart failure. Lancet. 1987;2:709-711.
53. Nordrehaug JE, Omsjø IH, Vollset SE. A 3-month double-blind cross-over study of the effect of benazepril and hydrochlorothiazide on functional class in symptomatic mild heart failure. J Intern Med. 1992;231:589-594.
54. Cowley AJ, Stainer K, Wynne RD, et al. Symptomatic assessment of patients with heart failure: double-blind comparison of increasing doses of diuretics and captopril in moderate heart failure. Lancet. 1986;2:770-772.
55. Boccanelli A, Zachara E, Liberatore SM, et al. Addition of captopril versus increasing diuretics in moderate but deteriorating heart failure: a double-blind comparative trial. Postgrad Med J. 1986;62(Suppl. 1):184-187.
56. Sievert H, Offermann T, Hopf R, et al. Basic therapy of chronic heart failure with digitalis or diuretics [in German]? Dtsch Med Wochenschr. 1989;114:363-367.